Breaking News
Investing Pro 0
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER

Intercept (ICPT) Gains 7.5% YTD On Progress In NASH Space

By Zacks Investment ResearchStock MarketsDec 01, 2019 09:04PM ET
www.investing.com/analysis/intercept-icpt-gains-75-ytd-on-progress-in-nash-space-200489345
Intercept (ICPT) Gains 7.5% YTD On Progress In NASH Space
By Zacks Investment Research   |  Dec 01, 2019 09:04PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
GILD
-0.86%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NVS
+1.08%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ICPT
-0.55%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
HSTO
+1.56%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) have gained 7.5% in the first eleven months of 2019 compared with the industry’s growth of 5.4%.

Notably, shares gained significantly after the company announced that the FDA accepted its New Drug Application (NDA) for obeticholic acid (OCA) seeking accelerated approval for the treatment of fibrosis due to NASH. The regulatory agency also granted Priority Review to the same. The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date of Mar 26, 2020, to the NDA. The agency indicated to hold an advisory committee meeting to discuss the application. However, the date is yet to be finalized and the timeline for the review is subject to change.

A potential approval of OCA for NASH will significantly boost Intercept’s prospects, given the market opportunity in fibrosis due to NASH.

A chronic liver disease, NASH, is caused by excessive fat accumulation in the liver or steatosis. Per statistics, it affected up to 15 million people in the United States causing inflammation, hepatocellular injury, progressive fibrosis and cirrhosis. The ailment is anticipated to be the leading reason for liver transplantation by 2020.

With no treatments presently approved to address this disease, the market scope is substantially huge and the winner so far in the race seems to be Intercept.

OCA is already approved under the brand name Ocaliva for the treatment of primary biliary cholangitis (“PBC”) in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. The uptake of the drug for the treatment of PBC in adults has been impressive, even though the safety and dosing issues for the same were earlier under the scanner. The company expanded its sales force to reach out to more physicians. Hence, sales have gained traction and are expected to pick up further.

While the lack of other candidates in the company’s pipeline is a concern, we are quite positive about the company’s progress to advance OCA in NASH as it is now the forerunner in the same space.

We remind investors that there have been quite a few setbacks in the NASH space this year. In June, Conatus Pharmaceuticals (NASDAQ:CNAT) announced that top-line results from the ENCORE-LF clinical study of emricasan failed to meet its primary endpoint. Consequently, Conatus and partner Novartis (NYSE:NVS) mutually agreed to cease the collaboration agreement for the global development and commercialization of the drug. Earlier, biotech bigwig Gilead Sciences, Inc. (NASDAQ:GILD) too suffered a setback with the failure of a late-stage study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH.

Intercept currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

Download Free Report Now >>



Novartis AG (NVS): Free Stock Analysis Report

Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report

Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Original post

Zacks Investment Research
Intercept (ICPT) Gains 7.5% YTD On Progress In NASH Space
 

Related Articles

Intercept (ICPT) Gains 7.5% YTD On Progress In NASH Space

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email